RU2467008C2 - IMIDAZO[1, 2-a]PYRIDINE COMPOUNDS AS INHIBITORS OF RECEPTOR TYROSINKINASES - Google Patents
IMIDAZO[1, 2-a]PYRIDINE COMPOUNDS AS INHIBITORS OF RECEPTOR TYROSINKINASES Download PDFInfo
- Publication number
- RU2467008C2 RU2467008C2 RU2009140407/04A RU2009140407A RU2467008C2 RU 2467008 C2 RU2467008 C2 RU 2467008C2 RU 2009140407/04 A RU2009140407/04 A RU 2009140407/04A RU 2009140407 A RU2009140407 A RU 2009140407A RU 2467008 C2 RU2467008 C2 RU 2467008C2
- Authority
- RU
- Russia
- Prior art keywords
- pyridin
- imidazo
- yloxy
- compound
- methoxyethoxy
- Prior art date
Links
- 0 Bc1c(*)c2nc(*)c(-c3c(*)c(*)c(c(*)c(*)c(*)c4OC(*CC(C)N(*)C5)C5O)c4n3)[n]2c(C)c1* Chemical compound Bc1c(*)c2nc(*)c(-c3c(*)c(*)c(c(*)c(*)c(*)c4OC(*CC(C)N(*)C5)C5O)c4n3)[n]2c(C)c1* 0.000 description 1
- PAXANHPWDOGPQX-UHFFFAOYSA-N Cc(cc1)ccc1S(C[N+]#C)(=O)=O Chemical compound Cc(cc1)ccc1S(C[N+]#C)(=O)=O PAXANHPWDOGPQX-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/06—Antianaemics
Abstract
FIELD: chemistry.
SUBSTANCE: compounds, which have formula I , in which A, B, R1, R1a, R2, R3, R4, R5 R6, R7 and R8 have values given in description and are inhibitors of receptor tyrosinkinases, useful in treatment of diseases, mediated by class 3 and class 5 receptor tyrosinkinases. It has been also discovered that specific compounds of the claimed invention are Pim-1 inhibitors. Also claimed is method of obtaining formula I compound.
EFFECT: increase of compound efficiency.
27 cl, 51 ex
Description
Claims (27)
или его фармацевтически приемлемая соль, где
А представляет собой -Z-(CH2)p-(hetCyc2a), -Z-(hetCyc2b), Z-R10 или Z-R11;
Z представляет собой О или NH;
p равен 0, 1 или 2;
hetCyc2a представляет собой 5 или 6-членное гетероциклическое кольцо, имеющее в своем составе 1-2 гетероатома, независимо выбираемых из N или О, необязательно замещенное одной или двумя группами R9;
hetCyc2b представляет собой 7-12-членную мостиковую гетеробициклическую систему, имеющую в своем составе 1-2 гетероатома, независимо выбираемых из N или О;
R10 представляет собой (1-6С)алкил, замещенный NR'R";
R11 представляет собой (5-6С)циклоалкил, замещенный NR'R";
В представляет собой ORh, hetAr2 или (1-3С)алкил;
R1, R2, R3 и R4 независимо являются Н, F, Cl или hetAr3;
R1а представляет собой Н, F или Cl;
R5, R6, R7 и R8 являются Н;
каждую группу R9 независимо выбирают из галогена, (1-6С)алкила, ORa и С(O)2(1-6Салкила);
каждая группа Ra независимо является Н или (1-6С)алкилом;
Rh представляет собой (1-6Салкил)-(3-6Сциклоалкил), (1-6Салкил)-O-(1-6Салкил);
hetCyc4 является 5 или 6-членным гетероциклическим кольцом, имеющим в своем составе атом кислорода;
hetAr2 представляет собой 5-6-членное гетероарильное кольцо, имеющее в своем составе 1-2 атома азота;
hetAr3 является 5-6-членным гетероарильным кольцом, имеющим в своем составе атом азота, и необязательно имеющее второй гетероатом, выбираемый из N или О;
и R' и R" независимо являются Н или (1-6С)алкилом.1. The compound of General formula I:
or its pharmaceutically acceptable salt, where
A is —Z— (CH 2 ) p - (hetCyc 2a ), —Z— (hetCyc 2b ), ZR 10 or ZR 11 ;
Z represents O or NH;
p is 0, 1 or 2;
hetCyc 2a is a 5 or 6 membered heterocyclic ring having 1 to 2 heteroatoms independently selected from N or O, optionally substituted with one or two R 9 groups;
hetCyc 2b is a 7-12 membered bridging heterobicyclic system having 1-2 heteroatoms independently selected from N or O;
R 10 represents (1-6C) alkyl substituted with NR'R ";
R 11 represents (5-6C) cycloalkyl substituted with NR'R ";
B is OR h , hetAr 2 or (1-3C) alkyl;
R 1 , R 2 , R 3 and R 4 are independently H, F, Cl or hetAr 3 ;
R 1a represents H, F or Cl;
R 5 , R 6 , R 7 and R 8 are H;
each R 9 group is independently selected from halogen, (1-6C) alkyl, OR a and C (O) 2 (1-6Calkyl);
each R a group is independently H or (1-6C) alkyl;
R h represents (1-6Calkyl) - (3-6Cycloalkyl), (1-6Calkyl) -O- (1-6Calkyl);
hetCyc 4 is a 5 or 6 membered heterocyclic ring having an oxygen atom;
hetAr 2 is a 5-6 membered heteroaryl ring having 1 to 2 nitrogen atoms;
hetAr 3 is a 5-6 membered heteroaryl ring having a nitrogen atom and optionally having a second heteroatom selected from N or O;
and R 'and R "are independently H or (1-6C) alkyl.
-ОСН2(циклопропила), этила, 2-пиридила, 3-пиридила, 4-пиридила, 2-пиримидила,
и 11. The compound according to claim 1, where B is selected from —OCH 2 CH 2 OCH 3 , —OCH 2 CH 2 OH,
-OSH 2 (cyclopropyl), ethyl, 2-pyridyl, 3-pyridyl, 4-pyridyl, 2-pyrimidyl,
and
и 13. The compound according to claim 12, wherein B is selected from —OCH 2 CH 2 OCH 3 , —OCH 2 CH 2 OH, —OCH 2 (cyclopropyl),
and
(а) для соединения формулы I, где А представляет собой -NH-(CH2)n(hetCyc2a), -NH-(hetCyc2b), NHR10 или NHR11, реакцию сочетания соответствующего соединения формулы II
где L1 представляет собой уходящую группу или атом, с соединением формулы H2N(CH2)n(hetCyc2a), H2N-hetCyc2b, NH2R10 или NH2 11, с помощью палладиевого катализатора и лиганда в присутствии основания; или
(b) для соединения формулы I, где В представляет собой OR11,
взаимодействие соответствующего соединения формулы III
с соединением формулы Rh-L2, где L2 представляет собой уходящую группу, в присутствии основания; или
(c) для соединения формулы I, где В представляет собой ORh, взаимодействие соответствующего соединения формулы III с соединением формулы Rh-OH в присутствии реагента сочетания; или
(d) для соединения формулы I, где А представляет собой -O-(CH2)nhetCyc2a, -O-hetCyc2b, OR10 или OR11, взаимодействие соответствующего соединения формулы IV
с соответствующим соединением формулы HO-(CH2)nhetCyc2a, НО-hetCyc2b, HOR10 или HOR11, в присутствии агента сочетания и трифенилфосфина в подходящем растворителе; или
е) для соединения формулы I, где А представляет собой -O-(CH2)n-hetCyc2a, взаимодействие соединения формулы IV с соединением формулы MeSO2-O(CH2)nhetCyc2a в присутствии основания; или
(f) для соединения формулы I, где R3 представляет собой hetAr3 и hetAr3 представляет собой оксазолил,
циклизация соединения формулы V
с соединением формулы
в присутствии основания; или
(g) для соединения формулы I, где А представляет собой
и n равен 1 или 2, взаимодействие соответствующего соединения формулы IV
с соединением формулы
где n равен 1 или 2 и Р1 представляет собой группу, защищающую амин, в присутствии основания; или
(h) для соединения формулы I, где А представляет собой:
и n равен 1 или 2,
взаимодействие соответствующего соединения формулы VII
где n равен 1 или 2 и Р2 представляет собой Н или группу, защищающую амин, с соединением формулы (1-6Салкил)L3, где L3 представляет собой уходящую группу или атом в присутствии основания; или
(i) для соединения формулы I, где А представляет собой O-(1-6Салкил)NR'R", взаимодействие соединения формулы IV
с соединением формулы L4-(1-6Caлкил)NR'R", где L4 представляет собой уходящую группу или атом, в присутствии основания и необязательно в присутствии катализатора межфазного переноса; или
(j) для соединения формулы I, где А представляет собой:
m равен 0, 1 или 2 и n равен 1 или 2, Р3 представляет собой Н или (1-6С)алкил,
взаимодействие соответствующего соединения формулы VIII
с соединением формулы НС(O)Р3а, где Р3a представляет собой Н или (1-6С)алкил, в присутствии восстановителя; и
удаление любой защитной группы или групп и необязательно образование фармацевтически приемлемой соли.23. The method of obtaining the compound according to claim 1, which includes:
(a) for a compound of formula I, wherein A is —NH— (CH 2 ) n (hetCyc 2a ), —NH— (hetCyc 2b ), NHR 10 or NHR 11 , a coupling reaction of the corresponding compound of formula II
where L 1 represents a leaving group or atom, with a compound of the formula H 2 N (CH 2 ) n (hetCyc 2a ), H 2 N-hetCyc 2b , NH 2 R 10 or NH 2 11 , using a palladium catalyst and a ligand in the presence of grounds; or
(b) for a compound of formula I, wherein B is OR 11 ,
the interaction of the corresponding compounds of formula III
with a compound of the formula R h —L 2 where L 2 is a leaving group in the presence of a base; or
(c) for a compound of formula I, wherein B is OR h , reacting the corresponding compound of formula III with a compound of formula R h —OH in the presence of a coupling reagent; or
(d) for a compound of formula I, wherein A is —O— (CH 2 ) n hetCyc 2a , —O-hetCyc 2b , OR 10 or OR 11 , reaction of the corresponding compound of formula IV
with the corresponding compound of the formula HO- (CH 2 ) n hetCyc 2a , HO-hetCyc 2b , HOR 10 or HOR 11 , in the presence of a coupling agent and triphenylphosphine in a suitable solvent; or
e) for a compound of formula I where A is —O— (CH 2 ) n —hetCyc 2a , reacting a compound of formula IV with a compound of formula MeSO 2 —O (CH 2 ) n hetCyc 2a in the presence of a base; or
(f) for a compound of formula I, wherein R 3 is hetAr 3 and hetAr 3 is oxazolyl,
cyclization of the compounds of formula V
with a compound of the formula
in the presence of a base; or
(g) for a compound of formula I, wherein A is
and n is 1 or 2, the interaction of the corresponding compounds of formula IV
with a compound of the formula
where n is 1 or 2 and P 1 represents an amine protecting group in the presence of a base; or
(h) for a compound of formula I, wherein A is:
and n is 1 or 2,
the interaction of the corresponding compounds of formula VII
where n is 1 or 2 and P 2 represents H or an amine protecting group with a compound of the formula (1-6Calkyl) L 3 , where L 3 represents a leaving group or atom in the presence of a base; or
(i) for a compound of formula I, wherein A is O- (1-6Calkyl) NR'R ", reaction of a compound of formula IV
with a compound of the formula L 4 - (1-6Calkyl) NR'R ", where L 4 represents a leaving group or atom, in the presence of a base and optionally in the presence of a phase transfer catalyst; or
(j) for a compound of formula I, wherein A is:
m is 0, 1 or 2 and n is 1 or 2, P 3 represents H or (1-6C) alkyl,
the interaction of the corresponding compounds of formula VIII
with a compound of the formula HC (O) P 3a , where P 3a is H or (1-6C) alkyl, in the presence of a reducing agent; and
removing any protecting group or groups and optionally forming a pharmaceutically acceptable salt.
(R)-2-(7-(2-метоксиэтокси)имидазо[1,2-а]пиридин-3-ил)-N-(пирролидин-3-ил)хинолин-8-амина;
(S)-2-(7-(2-метоксиэтокси)имидазо[1,2-а]пиридин-3-ил)-N-(пирролидин-3-ил)хинолин-8-амина;
2-(7-(2-метоксиэтокси)имидазо[1,2-а]пиридин-3-ил)-8-(пиперидин-4-илокси)хинолина;
(R)-2-(7-(2-метоксиэтокси)имидазо[1,2-а]пиридин-3-ил)-8-(пирролидин-3-илокси)хинолина;
(S)-2-(7-(2-метоксиэтокси)имидазо[1,2-а]пиридин-3-ил)-8-(пирролидин-3-илокси)хинолина;
2-(7-(2-метоксиэтокси)имидазо[1,2-а]пиридин-3-ил)-8-(2-(пиперидин-2-ил)этокси)хинолина;
2-(7-(2-метоксиэтокси)имидазо[1,2-а]пиридин-3-ил)-8-(пиперидин-3-илметокси)хинолина;
8-(8-азабицикло[3.2.1]октан-3-илокси)-2-(7-(2-метоксиэтокси)имидазо[1,2-а]пиридин-3-ил)хинолина;
3-(2-(7-(2-метоксиэтокси)имидазо[1,2-а]пиридин-3-ил)хинолин-8-илокси)-2,2-диметилпропан-1 -амина;
(1R,4R)-4-(2-(7-(2-метоксиэтокси)имидазо[1,2-а]пиридин-3-ил)хинолин-8-илокси)циклогексанамина;
(2S,4R)-метил4-(2-(7-(2-метоксиэтокси)имидазо[1,2-а]пиридин-3-ил)хинолин-8-илокси)пирролидин-2-карбоксилата;
(2S,4S)-метил4-(2-(7-(2-метоксиэтокси)имидазо[1,2-а]пиридин-3-ил)хинолин-8-илокси)пирролидин-2-карбоксилата;
(S)-3-((2-(7-(2-метоксиэтокси)имидазо[1,2-а]пиридин-3-ил)хинолин-8-илокси)метил)морфолина;
8-((цис)-4-фторпирролидин-3-илокси)-2-(7-(2-метоксиэтокси)имидазо[1,2-а]пиридин-3-ил)хинолина;
3-(2-(7-(2-метоксиэтокси)имидазо[1,2-а]пиридин-3-ил)хинолин-8-илокси)-N,N,2,2-тетраметилпропан-1-амина;
2-((2-(7-(2-метоксиэтокси)имидазо[1,2-а]пиридин-3-ил)хинолин-8-илокси)метил)морфолина;
2-(7-(2-метоксиэтокси)имидазо[1,2-а]пиридин-3-ил)-8-(пиперидин-4-илметокси)хинолина;
7-(2-(7-(2-метоксиэтокси)имидазо[1,2-а]пиридин-3-ил)хинолин-8-илокси)-3-окса-9-азабицикло[3.3.1]ионаиа;
8-((цис)-3-фторпиперидин-4-илокси)-2-(7-(2-метоксиэтокси)имидазо[1,2-а]пиридин-3-ил)хинолина;
8-((3S,4S)-3-фторпиперидин-4-илокси)-2-(7-(2-метоксиэтокси)имидазо[1,2-а]пиридин-3-ил)хинолина;
8-((3R,4R)-3-фторпиперидин-4-илокси)-2-(7-(2-метоксиэтокси)имидазо[1,2-а]пиридин-3-ил)хинолина;
(S)-2-(7-(2-метоксиэтокси)имидазо[1,2-а]пиридин-3-ил)-8-(пиперидин-3-илокси)хинолина;
(R)-2-(7-(2-метоксиэтокси)имидазо[1,2-а]пиридин-3-ил)-8-(пиперидин-3-илокси)хинолина;
(R)-2-(7-(2-метоксиэтокси)имидазо[1,2-а]пиридин-3-ил)-8-(пирролидин-2-илметокси)хинолина;
2-(7-(2-метоксиэтокси)имидазо[1,2-а]пиридин-3-ил)-8-(пирролидин-3-илметокси)хинолина;
5-(8-((транс)-3-фторпиперидин-4-илокси)-2-(7-(2-метоксиэтокси)имидазо[1,2-а]пиридин-3-ил)хииолин-4-ил)оксазола;
(транс)-4-(2-(7-(2-метоксиэтокси)имидазо[1,2-а]пиридин-3-ил)хинолин-8-илокси)пирролидин-3-ола;
2-(7-(2-метоксиэтокси)имидазо[1,2-а]пиридин-3-ил)-8-((транс)-4-метоксипирролидин-3-илокси)хинолина;
(транс)-4-(2-(7-(2-метоксиэтокси)имидазо[1,2-а]пиридин-3-ил)хинолин-8-илокси)пиперидин-3-ола;
8-((4-фторпиперидин-4-ил)метокси)-2-(7-(2-метоксиэтокси)имидазо[1,2-а]пиридин-3-ил)хинолина;
(цис)-4-(2-(7-(2-метоксиэтокси)имидазо[1,2-а]пиридин-3-ил)хинолин-8-илокси)пиперидин-3-ола;
N-((цис)-3-фторпиперидин-4-ил)-2-(7-(2-метоксиэтокси)имидазо[1,2-а]пиридин-3-ил)хинолин-8-амииа;
8-((транс)-3-фторпиперидин-4-илокси)-2-(7-(тетрагидро-2Н-пиран-4-илокси)имидазо[1,2-а]пиридин-3-ил)хинолина;
2-(7-(циклопропилметокси)имидазо[1,2-а]пиридин-3-ил)-8-((транс)-3-фторпиперидин-4-илокси)хинолина;
8-((транс)-3-фторпиперидин-4-илокси)-2-(7-((R)-тетрагидрофуран-3-илокси)имидазо[1,2-а]пиридин-3-ил)хинолина;
8-((транс)-3-фторпиперидин-4-илокси)-2-(7-((S)-тетрагидрофуран-3-илокси)имидазо[1,2-а]пиридин-3-ил)хинолина;
2-(2-(7-(2-метоксиэтокси)имидазо[1,2-а]пиридин-3-ил)хинолин-8-илокси)этанамина;
2-(7-этилимидазо[1,2-а]пиридин-3-ил)-8-((транс)-3-фторпиперидин-4-илокси)хинолина;
8-((транс)-3-фтор-1-метилпиперидин-4-илокси)-2-(7-(2-метоксиэтокси)имидазо[1,2-а]пиридин-3-ил)хинолина;
8-((транс)-1-этил-3-фторпиперидии-4-илокси)-2-(7-(2-метоксиэтокси)имидазо [1,2-а] пиридин-3-ил)хинолина;
2-(7-(2-метоксиэтокси)имидазо[1,2-а]пиридин-3-ил)-8-(1-метилпиперидин-4-илокси)хинолина;
8-(1-этилпиперидин-4-илокси)-2-(7-(2-метоксиэтокси)имидазо[1,2-а]пиридин-3-ил)хинолина;
2-(7-(2-метоксиэтокси)имидазо[1,2-а]пиридин-3-ил)-8-((1-метилпирролидин-3-ил)метокси)хинолина;
2-(7-(2-метоксиэтокси)имидазо [1,2-а]пиридин-3-ил)-N-(4-метилпиперидин-4-ил)хинолин-8-амина;
8-((транс)-3-фторпиперидин-4-илокси)-2-(7-(пиридин-3-ил)имидазо[1,2-а]пиридин-3-ил)хинолина;
8-(пиперидин-4-илокси)-2-(7-(пиридин-3-ил)имидазо[1,2-а]пиридин-3-ил)хинолина;
8-((цис)-4-фторпирролидин-3-илокси)-2-(7-(пиридин-3-ил)имидазо[1,2-а]пиридин-3-ил)хинолина;
2-(3-(8-(транс-3-фторпиперидин-4-илокси)хинолин-2-ил)имидазо[1,2-а]пиридин-7-илокси)этанола;
6-фтор-8-((3R,4R)-3-фторпиперидин-4-илокси)-2-(7-(2-метоксиэтокси)имидазо[1,2-а]пиридин-3-ил)хинолина;
8-((транс)-3-фторпиперидин-4-илокси)-2-(7-(пиримидин-5-ил)имидазо[1,2-а]пиридин-3-ил)хинолина;
8-((транс)-3-фторпиперидин-4-илокси)-2-(7-(4-метилпиридин-3-ил)имидазо[1,2-а]пиридин-3-ил)хинолина; и
5-фтор-8-((3R,4R)-3-фторпиперидин-4-илокси)-2-(7-(2-метоксиэтокси)имидазо[1,2-а]пиридин-3-ил)хинолина.24. The compound according to claim 1, which is selected from:
(R) -2- (7- (2-methoxyethoxy) imidazo [1,2-a] pyridin-3-yl) -N- (pyrrolidin-3-yl) quinolin-8-amine;
(S) -2- (7- (2-methoxyethoxy) imidazo [1,2-a] pyridin-3-yl) -N- (pyrrolidin-3-yl) quinolin-8-amine;
2- (7- (2-methoxyethoxy) imidazo [1,2-a] pyridin-3-yl) -8- (piperidin-4-yloxy) quinoline;
(R) -2- (7- (2-methoxyethoxy) imidazo [1,2-a] pyridin-3-yl) -8- (pyrrolidin-3-yloxy) quinoline;
(S) -2- (7- (2-methoxyethoxy) imidazo [1,2-a] pyridin-3-yl) -8- (pyrrolidin-3-yloxy) quinoline;
2- (7- (2-methoxyethoxy) imidazo [1,2-a] pyridin-3-yl) -8- (2- (piperidin-2-yl) ethoxy) quinoline;
2- (7- (2-methoxyethoxy) imidazo [1,2-a] pyridin-3-yl) -8- (piperidin-3-ylmethoxy) quinoline;
8- (8-azabicyclo [3.2.1] octan-3-yloxy) -2- (7- (2-methoxyethoxy) imidazo [1,2-a] pyridin-3-yl) quinoline;
3- (2- (7- (2-methoxyethoxy) imidazo [1,2-a] pyridin-3-yl) quinolin-8-yloxy) -2,2-dimethylpropan-1-amine;
(1R, 4R) -4- (2- (7- (2-methoxyethoxy) imidazo [1,2-a] pyridin-3-yl) quinolin-8-yloxy) cyclohexanamine;
(2S, 4R) methyl 4- (2- (7- (2-methoxyethoxy) imidazo [1,2-a] pyridin-3-yl) quinolin-8-yloxy) pyrrolidine-2-carboxylate;
(2S, 4S) methyl 4- (2- (7- (2-methoxyethoxy) imidazo [1,2-a] pyridin-3-yl) quinolin-8-yloxy) pyrrolidine-2-carboxylate;
(S) -3 - ((2- (7- (2-methoxyethoxy) imidazo [1,2-a] pyridin-3-yl) quinolin-8-yloxy) methyl) morpholine;
8 - ((cis) -4-fluoropyrrolidin-3-yloxy) -2- (7- (2-methoxyethoxy) imidazo [1,2-a] pyridin-3-yl) quinoline;
3- (2- (7- (2-methoxyethoxy) imidazo [1,2-a] pyridin-3-yl) quinolin-8-yloxy) -N, N, 2,2-tetramethylpropan-1-amine;
2 - ((2- (7- (2-methoxyethoxy) imidazo [1,2-a] pyridin-3-yl) quinolin-8-yloxy) methyl) morpholine;
2- (7- (2-methoxyethoxy) imidazo [1,2-a] pyridin-3-yl) -8- (piperidin-4-ylmethoxy) quinoline;
7- (2- (7- (2-methoxyethoxy) imidazo [1,2-a] pyridin-3-yl) quinolin-8-yloxy) -3-oxa-9-azabicyclo [3.3.1] ionaia;
8 - ((cis) -3-fluoropiperidin-4-yloxy) -2- (7- (2-methoxyethoxy) imidazo [1,2-a] pyridin-3-yl) quinoline;
8 - ((3S, 4S) -3-fluoropiperidin-4-yloxy) -2- (7- (2-methoxyethoxy) imidazo [1,2-a] pyridin-3-yl) quinoline;
8 - ((3R, 4R) -3-fluoropiperidin-4-yloxy) -2- (7- (2-methoxyethoxy) imidazo [1,2-a] pyridin-3-yl) quinoline;
(S) -2- (7- (2-methoxyethoxy) imidazo [1,2-a] pyridin-3-yl) -8- (piperidin-3-yloxy) quinoline;
(R) -2- (7- (2-methoxyethoxy) imidazo [1,2-a] pyridin-3-yl) -8- (piperidin-3-yloxy) quinoline;
(R) -2- (7- (2-methoxyethoxy) imidazo [1,2-a] pyridin-3-yl) -8- (pyrrolidin-2-ylmethoxy) quinoline;
2- (7- (2-methoxyethoxy) imidazo [1,2-a] pyridin-3-yl) -8- (pyrrolidin-3-ylmethoxy) quinoline;
5- (8 - ((trans) -3-fluoropiperidin-4-yloxy) -2- (7- (2-methoxyethoxy) imidazo [1,2-a] pyridin-3-yl) chiolin-4-yl) oxazole ;
(trans) -4- (2- (7- (2-methoxyethoxy) imidazo [1,2-a] pyridin-3-yl) quinolin-8-yloxy) pyrrolidin-3-ol;
2- (7- (2-methoxyethoxy) imidazo [1,2-a] pyridin-3-yl) -8 - ((trans) -4-methoxypyrrolidin-3-yloxy) quinoline;
(trans) -4- (2- (7- (2-methoxyethoxy) imidazo [1,2-a] pyridin-3-yl) quinolin-8-yloxy) piperidin-3-ol;
8 - ((4-fluoropiperidin-4-yl) methoxy) -2- (7- (2-methoxyethoxy) imidazo [1,2-a] pyridin-3-yl) quinoline;
(cis) -4- (2- (7- (2-methoxyethoxy) imidazo [1,2-a] pyridin-3-yl) quinolin-8-yloxy) piperidin-3-ol;
N - ((cis) -3-fluoropiperidin-4-yl) -2- (7- (2-methoxyethoxy) imidazo [1,2-a] pyridin-3-yl) quinolin-8-amia;
8 - ((trans) -3-fluoropiperidin-4-yloxy) -2- (7- (tetrahydro-2H-pyran-4-yloxy) imidazo [1,2-a] pyridin-3-yl) quinoline;
2- (7- (cyclopropylmethoxy) imidazo [1,2-a] pyridin-3-yl) -8 - ((trans) -3-fluoropiperidin-4-yloxy) quinoline;
8 - ((trans) -3-fluoropiperidin-4-yloxy) -2- (7 - ((R) -tetrahydrofuran-3-yloxy) imidazo [1,2-a] pyridin-3-yl) quinoline;
8 - ((trans) -3-fluoropiperidin-4-yloxy) -2- (7 - ((S) -tetrahydrofuran-3-yloxy) imidazo [1,2-a] pyridin-3-yl) quinoline;
2- (2- (7- (2-methoxyethoxy) imidazo [1,2-a] pyridin-3-yl) quinolin-8-yloxy) ethanamine;
2- (7-ethylimidazo [1,2-a] pyridin-3-yl) -8 - ((trans) -3-fluoropiperidin-4-yloxy) quinoline;
8 - ((trans) -3-fluoro-1-methylpiperidin-4-yloxy) -2- (7- (2-methoxyethoxy) imidazo [1,2-a] pyridin-3-yl) quinoline;
8 - ((trans) -1-ethyl-3-fluoropiperidium-4-yloxy) -2- (7- (2-methoxyethoxy) imidazo [1,2-a] pyridin-3-yl) quinoline;
2- (7- (2-methoxyethoxy) imidazo [1,2-a] pyridin-3-yl) -8- (1-methylpiperidin-4-yloxy) quinoline;
8- (1-ethylpiperidin-4-yloxy) -2- (7- (2-methoxyethoxy) imidazo [1,2-a] pyridin-3-yl) quinoline;
2- (7- (2-methoxyethoxy) imidazo [1,2-a] pyridin-3-yl) -8 - ((1-methylpyrrolidin-3-yl) methoxy) quinoline;
2- (7- (2-methoxyethoxy) imidazo [1,2-a] pyridin-3-yl) -N- (4-methylpiperidin-4-yl) quinolin-8-amine;
8 - ((trans) -3-fluoropiperidin-4-yloxy) -2- (7- (pyridin-3-yl) imidazo [1,2-a] pyridin-3-yl) quinoline;
8- (piperidin-4-yloxy) -2- (7- (pyridin-3-yl) imidazo [1,2-a] pyridin-3-yl) quinoline;
8 - ((cis) -4-fluoropyrrolidin-3-yloxy) -2- (7- (pyridin-3-yl) imidazo [1,2-a] pyridin-3-yl) quinoline;
2- (3- (8- (trans-3-fluoropiperidin-4-yloxy) quinolin-2-yl) imidazo [1,2-a] pyridin-7-yloxy) ethanol;
6-fluoro-8 - ((3R, 4R) -3-fluoropiperidin-4-yloxy) -2- (7- (2-methoxyethoxy) imidazo [1,2-a] pyridin-3-yl) quinoline;
8 - ((trans) -3-fluoropiperidin-4-yloxy) -2- (7- (pyrimidin-5-yl) imidazo [1,2-a] pyridin-3-yl) quinoline;
8 - ((trans) -3-fluoropiperidin-4-yloxy) -2- (7- (4-methylpyridin-3-yl) imidazo [1,2-a] pyridin-3-yl) quinoline; and
5-fluoro-8 - ((3R, 4R) -3-fluoropiperidin-4-yloxy) -2- (7- (2-methoxyethoxy) imidazo [1,2-a] pyridin-3-yl) quinoline.
где
L1 представляет собой уходящий атом или уходящую группу;
В представляет собой ORh, hetAr2 или (1-3С)алкил;
R1, R2, R3 и R4 независимо являются Н, F, Cl или hetAr3;
R1a представляет собой Н, F или Cl;
R5, R6, R7 и R8 являются Н;
Rh представляет собой (1-6Салкил)-(3-6Сциклоалкил), (1-6Салкил)-O-(1-6Салкил) или hetCyc4;
hetCyc4 является 5 или 6-членным гетероциклическим кольцом, имеющим в своем составе атом кислорода;
hetAr2 представляет собой 5-6-членное гетероарильное кольцо, имеющее в своем составе 1-2 атома азота; и
hetAr3 представляет собой 5-6-членное гетероарильное кольцо, имеющее в своем составе атом азота и необязательно имеющее второй гетероатом, выбираемый из N или О.25. The compound of the formula:
Where
L 1 represents a leaving atom or a leaving group;
B is OR h , hetAr 2 or (1-3C) alkyl;
R 1 , R 2 , R 3 and R 4 are independently H, F, Cl or hetAr 3 ;
R 1a represents H, F or Cl;
R 5 , R 6 , R 7 and R 8 are H;
R h represents (1-6Cialkyl) - (3-6Cycloalkyl), (1-6CiCyl) -O- (1-6CiCiO) or hetCyc 4 ;
hetCyc 4 is a 5 or 6 membered heterocyclic ring having an oxygen atom;
hetAr 2 is a 5-6 membered heteroaryl ring having 1 to 2 nitrogen atoms; and
hetAr 3 is a 5-6 membered heteroaryl ring having a nitrogen atom and optionally having a second heteroatom selected from N or O.
где
А представляет собой -Z-(CH2)p-(hetCyc2a), -Z-(hetCyc2b), Z-R10 или Z-R11;
Z представляет собой О или NH;
p равен 0, 1, или 2;
hetCyc2a представляет собой 5 или 6-членное гетероциклическое кольцо, имеющее в своем составе 1-2 гетероатома, независимо выбираемые из N или О, необязательно замещенное одной или двумя группами R9;
hetCyc2b представляет собой 7-12-членную мостиковую гетеробициклическую систему, имеющую в своем составе 1-2 гетероатома, независимо выбираемые из N или О;
R10 представляет собой (1-6С)алкил, замещенный NR'R";
R11 представляет собой (5-6С)циклоалкил, замещенный NR'R";
R1, R2, R3 и R4 независимо являются Н, F, Cl или hetAr3;
R1a представляет собой Н, F или Cl;
R5, R6, R7 и R8 являются Н;
каждую группу R9 независимо выбирают из галогена, (1-6С)алкила, OR3 и С(O)O(1-6Салкила);
каждая группа R3 независимо является Н или (1-6С)алкилом;
hetAr3 является 5-6-членным гетероарильным кольцом, имеющим в своем составе атом азота, и необязательно имеющее второй гетероатом, выбираемый из N или О; и
R' и R" независимо являются Н или (1-6С)алкилом.26. The compound of the formula:
Where
A is —Z— (CH 2 ) p - (hetCyc 2a ), —Z— (hetCyc 2b ), ZR 10 or ZR 11 ;
Z represents O or NH;
p is 0, 1, or 2;
hetCyc 2a is a 5 or 6 membered heterocyclic ring having 1 to 2 heteroatoms independently selected from N or O, optionally substituted with one or two R 9 groups;
hetCyc 2b is a 7-12 membered heterobicyclic bridging system having 1-2 heteroatoms independently selected from N or O;
R 10 represents (1-6C) alkyl substituted with NR'R ";
R 11 represents (5-6C) cycloalkyl substituted with NR'R ";
R 1 , R 2 , R 3 and R 4 are independently H, F, Cl or hetAr 3 ;
R 1a represents H, F or Cl;
R 5 , R 6 , R 7 and R 8 are H;
each R 9 group is independently selected from halogen, (1-6C) alkyl, OR 3 and C (O) O (1-6Calkyl);
each R 3 group is independently H or (1-6C) alkyl;
hetAr 3 is a 5-6 membered heteroaryl ring having a nitrogen atom and optionally having a second heteroatom selected from N or O; and
R 'and R "independently are H or (1-6C) alkyl.
где
В представляет собой ORh, hetAr2 или (1-3С)алкил;
R1, R2, R3 и R4 независимо являются Н, F, Cl или hetAr3;
R1a представляет собой Н, F или Cl;
R5, R6, R7 и R8 являются Н;
Rh представляет собой (1-6Салкил)-(3-6Сциклоалкил), (1-6Салкил)-O-(1-6Салкил) или hetCyc4;
hetCyc4 является 5 или 6-членным гетероциклическим кольцом, имеющим в своем составе атом кислорода;
hetAr2 представляет собой 5-6-членное гетероарильное кольцо, имеющее в своем составе 1-2 атома азота; и
hetAr3 представляет собой 5-6-членное гетероарильное кольцо, имеющее в своем составе атом азота и необязательно имеющее второй гетероатом, выбираемый из N или О. 27. The compound of the formula:
Where
B is OR h , hetAr 2 or (1-3C) alkyl;
R 1 , R 2 , R 3 and R 4 are independently H, F, Cl or hetAr 3 ;
R 1a represents H, F or Cl;
R 5 , R 6 , R 7 and R 8 are H;
R h represents (1-6Cialkyl) - (3-6Cycloalkyl), (1-6CiCyl) -O- (1-6CiCiO) or hetCyc 4 ;
hetCyc 4 is a 5 or 6 membered heterocyclic ring having an oxygen atom;
hetAr 2 is a 5-6 membered heteroaryl ring having 1 to 2 nitrogen atoms; and
hetAr 3 is a 5-6 membered heteroaryl ring having a nitrogen atom and optionally having a second heteroatom selected from N or O.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US90985707P | 2007-04-03 | 2007-04-03 | |
US60/909,857 | 2007-04-03 |
Publications (2)
Publication Number | Publication Date |
---|---|
RU2009140407A RU2009140407A (en) | 2011-05-10 |
RU2467008C2 true RU2467008C2 (en) | 2012-11-20 |
Family
ID=39539641
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
RU2009140407/04A RU2467008C2 (en) | 2007-04-03 | 2008-03-27 | IMIDAZO[1, 2-a]PYRIDINE COMPOUNDS AS INHIBITORS OF RECEPTOR TYROSINKINASES |
Country Status (26)
Country | Link |
---|---|
US (1) | US8138181B2 (en) |
EP (1) | EP2137184B1 (en) |
JP (1) | JP5374492B2 (en) |
KR (1) | KR101538179B1 (en) |
CN (2) | CN103214482B (en) |
AU (1) | AU2008237507B2 (en) |
BR (1) | BRPI0809998B8 (en) |
CA (1) | CA2682981C (en) |
CO (1) | CO6251377A2 (en) |
CY (1) | CY1114277T1 (en) |
DK (1) | DK2137184T3 (en) |
ES (1) | ES2420113T3 (en) |
HK (1) | HK1140200A1 (en) |
HR (1) | HRP20130660T1 (en) |
IL (1) | IL201300A0 (en) |
MX (1) | MX2009010728A (en) |
MY (1) | MY157724A (en) |
NZ (1) | NZ580327A (en) |
PL (1) | PL2137184T3 (en) |
PT (1) | PT2137184E (en) |
RS (1) | RS52862B (en) |
RU (1) | RU2467008C2 (en) |
TW (1) | TWI429434B (en) |
UA (1) | UA101611C2 (en) |
WO (1) | WO2008124323A1 (en) |
ZA (1) | ZA200907674B (en) |
Families Citing this family (73)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
PL2474545T3 (en) | 2005-12-13 | 2017-04-28 | Incyte Holdings Corporation | Heteroaryl substituted pyrrolo[2,3-b]pyridines and pyrrolo[2,3-b]pyrimidines as Janus kinase inhibitors |
CA2672213C (en) | 2006-12-22 | 2016-02-16 | Astex Therapeutics Limited | Bicyclic amine derivatives as protein tyrosine kinase inhibitors |
US8895745B2 (en) | 2006-12-22 | 2014-11-25 | Astex Therapeutics Limited | Bicyclic heterocyclic compounds as FGFR inhibitors |
HUE043732T2 (en) | 2007-06-13 | 2019-09-30 | Incyte Holdings Corp | Use of salts of the janus kinase inhibitor (r)-3-(4-(7h-pyrrolo[2,3-d]pyrimidin-4-yl)-1h- pyrazol-1-yl)-3- cyclopentylpropanenitrile |
GB0720041D0 (en) | 2007-10-12 | 2007-11-21 | Astex Therapeutics Ltd | New Compounds |
GB0720038D0 (en) | 2007-10-12 | 2007-11-21 | Astex Therapeutics Ltd | New compounds |
CA2726588C (en) | 2008-06-03 | 2019-04-16 | Karl Kossen | Compounds and methods for treating inflammatory and fibrotic disorders |
GB0810902D0 (en) | 2008-06-13 | 2008-07-23 | Astex Therapeutics Ltd | New compounds |
WO2010033941A1 (en) | 2008-09-22 | 2010-03-25 | Array Biopharma Inc. | Substituted imidazo[1,2b]pyridazine compounds as trk kinase inhibitors |
WO2010039825A2 (en) * | 2008-10-01 | 2010-04-08 | Array Biopharma Inc. | IMIDAZO[1,2-a]PYRIDINE COMPOUNDS AS RECEPTOR TYROSINE KINASE INHIBITORS |
UY32192A (en) * | 2008-10-22 | 2011-05-31 | Array Biopharma Inc | PIRAZOLO COMPOUNDS [1,5-a] PIRIMIDINE REPLACED AS TRK CINASA INHIBITORS |
GB0906472D0 (en) | 2009-04-15 | 2009-05-20 | Astex Therapeutics Ltd | New compounds |
GB0906470D0 (en) | 2009-04-15 | 2009-05-20 | Astex Therapeutics Ltd | New compounds |
AU2010249380B2 (en) | 2009-05-22 | 2015-08-20 | Incyte Holdings Corporation | N-(hetero)aryl-pyrrolidine derivatives of pyrazol-4-yl-pyrrolo[2,3-d]pyrimidines and pyrrol-3-yl-pyrrolo[2,3-d]pyrimidines as Janus kinase inhibitors |
CA2761954C (en) | 2009-05-22 | 2018-07-31 | Incyte Corporation | 3-[4-(7h-pyrrolo[2,3-d]pyrimidin-4-yl)-1h-pyrazol-1-yl]octane- or heptane-nitrile as jak inhibitors |
AR077468A1 (en) | 2009-07-09 | 2011-08-31 | Array Biopharma Inc | PIRAZOLO COMPOUNDS (1,5-A) PYRIMIDINE SUBSTITUTED AS TRK-QUINASA INHIBITORS |
TW201113285A (en) | 2009-09-01 | 2011-04-16 | Incyte Corp | Heterocyclic derivatives of pyrazol-4-yl-pyrrolo[2,3-d]pyrimidines as janus kinase inhibitors |
US20120220581A1 (en) | 2009-10-30 | 2012-08-30 | Janssen-Cilag, S.A. | IMIDAZO[1,2-b]PYRIDAZINE DERIVATIVES AND THEIR USE AS PDE10 INHIBITORS |
FR2953838B1 (en) * | 2009-12-10 | 2012-02-24 | Sanofi Aventis | TRISUBSTITUTED 9H-BETA-CARBOLINE (OR 9H-PYRIDINO [3,4-B] INDOLE) DERIVATIVES, THEIR PREPARATION AND THEIR THERAPEUTIC USE |
FR2953837B1 (en) * | 2009-12-10 | 2012-03-09 | Sanofi Aventis | DISUBSTITUTED 9H-PYRIDINO [3,4-B] INDOLE DERIVATIVES, THEIR PREPARATION AND THEIR THERAPEUTIC USE |
WO2011079076A1 (en) * | 2009-12-21 | 2011-06-30 | Array Biopharma Inc. | Substituted n-(1h-indazol-4-yl)imidazo[1, 2-a]pyridine-3- carboxamide compounds as cfms inhibitors |
AR080754A1 (en) | 2010-03-09 | 2012-05-09 | Janssen Pharmaceutica Nv | IMIDAZO DERIVATIVES (1,2-A) PIRAZINA AND ITS USE AS PDE10 INHIBITORS |
AR081315A1 (en) | 2010-03-10 | 2012-08-08 | Incyte Corp | HETEROCICLIC DERIVATIVES OF PIPERIDIN AND PIRIMIDIN -4-IL-AZETIDINA, A CRYSTALLINE FORM OF THE SALT OF ACETONITRILADIPICO ACID OF A PYRIMIDINIC DERIVATIVE, PHARMACEUTICAL COMPOSITIONS CONTAINING THEM AND USE OF THE SAME THINGS WITH THE TREATMENT OF INJECTION , T |
MX2012012145A (en) * | 2010-04-28 | 2012-11-21 | Daiichi Sankyo Co Ltd | [5,6] heterocyclic compound. |
HUE035337T2 (en) | 2010-05-20 | 2018-05-02 | Array Biopharma Inc | Macrocyclic compounds as TRK kinase inhibitors |
NZ603686A (en) | 2010-05-21 | 2014-11-28 | Incyte Corp | Topical formulation for a jak inhibitor |
JP5917544B2 (en) | 2010-11-19 | 2016-05-18 | インサイト・ホールディングス・コーポレイションIncyte Holdings Corporation | Heterocyclic substituted pyrrolopyridines and pyrrolopyrimidines as JAK inhibitors |
EA026201B1 (en) | 2010-11-19 | 2017-03-31 | Инсайт Холдингс Корпорейшн | Cyclobutyl substituted pyrrolopyridine and pyrrolopyrimidine derivatives as jak inhibitors |
ES2540996T3 (en) * | 2010-12-13 | 2015-07-15 | Array Biopharma, Inc. | Compounds of substituted N- (1H-indazol-4-yl) imidazo [1,2-a] pyridin-3-carboxamide as type III receptor tyrosine kinase inhibitors |
RS54586B1 (en) * | 2011-02-25 | 2016-08-31 | Array Biopharma Inc. | Triazolopyridine compounds as pim kinase inhibitors |
AR086983A1 (en) | 2011-06-20 | 2014-02-05 | Incyte Corp | DERIVATIVES OF AZETIDINIL FENIL, PIRIDIL OR PIRAZINIL CARBOXAMIDA AS JAK INHIBITORS |
US10604523B2 (en) | 2011-06-27 | 2020-03-31 | Janssen Pharmaceutica Nv | 1-aryl-4-methyl-[1,2,4]triazolo[4,3-a]quinoxaline derivatives |
WO2013005057A1 (en) | 2011-07-07 | 2013-01-10 | Centro Nacional De Investigaciones Oncológicas (Cnio) | New compounds |
TW201313721A (en) | 2011-08-18 | 2013-04-01 | Incyte Corp | Cyclohexyl azetidine derivatives as JAK inhibitors |
UA111854C2 (en) | 2011-09-07 | 2016-06-24 | Інсайт Холдінгс Корпорейшн | METHODS AND INTERMEDIATE COMPOUNDS FOR JAK INHIBITORS |
CN103214481B (en) * | 2012-01-21 | 2016-08-03 | 中国科学院上海药物研究所 | Novel imidazole also [1,2-a] pyridine compounds and their, its preparation method, comprise the medical composition and its use of this compounds |
AR091079A1 (en) | 2012-05-18 | 2014-12-30 | Incyte Corp | DERIVATIVES OF PIRROLOPIRIMIDINA AND PIRROLOPIRIDINA REPLACED WITH PIPERIDINILCICLOBUTILO AS JAK INHIBITORS |
JP6426603B2 (en) | 2012-06-26 | 2018-11-21 | ヤンセン ファーマシューティカ エヌ.ベー. | A PDE2 inhibitor such as a 1-aryl-4-methyl- [1,2,4] triazolo [4,3-a] -quinoxaline compound and a PDE10 inhibitor for use in the treatment of a neurological or metabolic disorder combination |
CN104411314B (en) | 2012-07-09 | 2017-10-20 | 詹森药业有限公司 | The inhibitor of phosphodiesterase 10 |
CA2886187C (en) | 2012-09-28 | 2020-04-14 | Vanderbilt University | Fused heterocyclic compounds as selective bmp inhibitors |
AR092742A1 (en) | 2012-10-02 | 2015-04-29 | Intermune Inc | ANTIFIBROTIC PYRIDINONES |
US9969694B2 (en) | 2012-11-13 | 2018-05-15 | Array Biopharma Inc. | N-(arylalkyl)-N′-pyrazolyl-urea, thiourea, guanidine and cyanoguanidine compounds as TrkA kinase inhibitors |
PL2919766T3 (en) | 2012-11-15 | 2021-10-04 | Incyte Holdings Corporation | Sustained-release dosage forms of ruxolitinib |
JP6437452B2 (en) | 2013-01-14 | 2018-12-12 | インサイト・ホールディングス・コーポレイションIncyte Holdings Corporation | Bicyclic aromatic carboxamide compounds useful as Pim kinase inhibitors |
DK2945939T3 (en) | 2013-01-15 | 2020-03-23 | Incyte Holdings Corp | THIAZOLIC CARBOXAMIDES AND PYRIDINE CARBOXAMIDE COMPOUNDS USED AS PIM KINASE INHIBITORS |
AU2014225938B2 (en) | 2013-03-06 | 2018-07-19 | Incyte Holdings Corporation | Processes and intermediates for making a JAK inhibitor |
EP2994142A4 (en) * | 2013-05-08 | 2017-03-29 | Colorado Seminary, Which Owns and Operates The University of Denver | Antibiotic and anti-parasitic agents that modulate class ii fructose 1,6-bisphosphate aldolase |
MX2016001639A (en) | 2013-08-07 | 2016-10-07 | Incyte Corp | Sustained release dosage forms for a jak1 inhibitor. |
AR097431A1 (en) | 2013-08-23 | 2016-03-16 | Incyte Corp | FUR CARBOXAMIDE COMPOUNDS AND TIENOPIRIDINE USEFUL AS PIM KINASE INHIBITORS |
MX2016012808A (en) | 2014-04-02 | 2017-01-05 | Intermune Inc | Anti-fibrotic pyridinones. |
WO2015184305A1 (en) | 2014-05-30 | 2015-12-03 | Incyte Corporation | TREATMENT OF CHRONIC NEUTROPHILIC LEUKEMIA (CNL) AND ATYPICAL CHRONIC MYELOID LEUKEMIA (aCML) BY INHIBITORS OF JAK1 |
US9580418B2 (en) | 2014-07-14 | 2017-02-28 | Incyte Corporation | Bicyclic aromatic carboxamide compounds useful as Pim kinase inhibitors |
WO2016010897A1 (en) | 2014-07-14 | 2016-01-21 | Incyte Corporation | Bicyclic heteroaromatic carboxamide compounds useful as pim kinase inhibitors |
KR102649887B1 (en) | 2014-11-16 | 2024-03-22 | 어레이 바이오파마 인크. | Crystalline form of (s)-n-(5-((r)-2-(2,5-difluorophenyl)-pyrrolidin-1-yl)-pyrazolo[1,5-a]pyrimidin-3-yl)-3-hydroxypyrrolidine-1-carboxamide hydrogen sulfate |
WO2016196244A1 (en) | 2015-05-29 | 2016-12-08 | Incyte Corporation | Pyridineamine compounds useful as pim kinase inhibitors |
AR105967A1 (en) | 2015-09-09 | 2017-11-29 | Incyte Corp | SALTS OF A PIM QUINASA INHIBITOR |
US9920032B2 (en) | 2015-10-02 | 2018-03-20 | Incyte Corporation | Heterocyclic compounds useful as pim kinase inhibitors |
TN2018000138A1 (en) | 2015-10-26 | 2019-10-04 | Array Biopharma Inc | Point mutations in trk inhibitor-resistant cancer and methods relating to the same |
MX2018012163A (en) | 2016-04-04 | 2019-07-08 | Loxo Oncology Inc | Liquid formulations of (s)-n-(5-((r)-2-(2,5-difluorophenyl)-pyrro lidin-1-yl)-pyrazolo[1,5-a]pyrimidin-3-yl)-3-hydroxypyrrolidine- 1-carboxamide. |
US10045991B2 (en) | 2016-04-04 | 2018-08-14 | Loxo Oncology, Inc. | Methods of treating pediatric cancers |
JP7443057B2 (en) | 2016-05-18 | 2024-03-05 | ロクソ オンコロジー, インコーポレイテッド | (S)-N-(5-((R)-2-(2,5-difluorophenyl)pyrrolidin-1-yl)-pyrazolo[1,5-a]pyrimidin-3-yl)-3-hydroxypyrrolidine -1-Preparation of carboxamide |
CN109952293A (en) * | 2016-09-14 | 2019-06-28 | 范德比尔特大学 | The inhibition of BMP signal transduction, compound, composition and application thereof |
JOP20190092A1 (en) | 2016-10-26 | 2019-04-25 | Array Biopharma Inc | PROCESS FOR THE PREPARATION OF PYRAZOLO[1,5-a]PYRIMIDINES AND SALTS THEREOF |
JOP20190213A1 (en) | 2017-03-16 | 2019-09-16 | Array Biopharma Inc | Macrocyclic compounds as ros1 kinase inhibitors |
US10596161B2 (en) | 2017-12-08 | 2020-03-24 | Incyte Corporation | Low dose combination therapy for treatment of myeloproliferative neoplasms |
DK3746429T3 (en) | 2018-01-30 | 2022-05-02 | Incyte Corp | PROCEDURES FOR THE PREPARATION OF (1- (3-FLUORO-2- (TRIFLUOROMETHYL) ISONICOTINYL) PIPERIDIN-4-ON) |
WO2019178383A1 (en) | 2018-03-14 | 2019-09-19 | Vanderbilt University | Inhibition of bmp signaling, compounds, compositions and uses thereof |
UA127925C2 (en) | 2018-03-30 | 2024-02-14 | Інсайт Корпорейшн | Treatment of hidradenitis suppurativa using jak inhibitors |
CN110833554B (en) * | 2018-08-15 | 2022-03-08 | 广西梧州制药(集团)股份有限公司 | Use of pyrazolopyrimidine derivatives for the treatment of autoimmune thyroid disorders |
MX2021005047A (en) | 2018-10-31 | 2021-09-08 | Gilead Sciences Inc | Substituted 6-azabenzimidazole compounds as hpk1 inhibitors. |
WO2020092528A1 (en) | 2018-10-31 | 2020-05-07 | Gilead Sciences, Inc. | Substituted 6-azabenzimidazole compounds having hpk1 inhibitory activity |
EP3972695A1 (en) | 2019-05-23 | 2022-03-30 | Gilead Sciences, Inc. | Substituted exo-methylene-oxindoles which are hpk1/map4k1 inhibitors |
US11833155B2 (en) | 2020-06-03 | 2023-12-05 | Incyte Corporation | Combination therapy for treatment of myeloproliferative neoplasms |
Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20050239822A1 (en) * | 2002-10-08 | 2005-10-27 | Gruenenthal Gmbh | Substituted C-imiadazol[1,2-a] pyridin-3-yl-methylamines |
US20050256309A1 (en) * | 2004-05-12 | 2005-11-17 | Altenbach Robert J | Tri-and bi-cyclic heteroaryl histamine-3 receptor ligands |
EP1235825B1 (en) * | 1999-11-30 | 2006-01-25 | Pfizer Products Inc. | Novel benzoimidazole derivatives useful as antiproliferative agents |
Family Cites Families (14)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
SK12472002A3 (en) * | 2000-03-06 | 2003-04-01 | Warner-Lambert Company | 5-Alkylpyrido[2,3-d]pyrimidines tyrosine kinase inhibitors |
CA2407573C (en) | 2000-04-27 | 2011-09-13 | Yamanouchi Pharmaceutical Co. Ltd. | Imidazopyridine derivatives |
MXPA03002032A (en) * | 2000-09-11 | 2003-07-24 | Chiron Corp | Quinolinone derivatives. |
SE0100567D0 (en) | 2001-02-20 | 2001-02-20 | Astrazeneca Ab | Compounds |
WO2002088107A1 (en) | 2001-04-26 | 2002-11-07 | Eisai Co., Ltd. | Nitrogenous fused-ring compound having pyrazolyl group as substituent and medicinal composition thereof |
US7125888B2 (en) | 2002-05-02 | 2006-10-24 | Merck & Co., Inc. | Tyrosine kinase inhibitors |
PA8580301A1 (en) | 2002-08-28 | 2005-05-24 | Pfizer Prod Inc | NEW BENZOIMIDAZOL DERIVATIVES USEFUL AS ANTIPROLIFERATIVE AGENTS |
PA8595001A1 (en) | 2003-03-04 | 2004-09-28 | Pfizer Prod Inc | NEW CONDENSED HETEROAROMATIC COMPOUNDS THAT ARE INHIBITORS OF THE TRANSFORMING GROWTH FACTOR (TGF) |
US7205316B2 (en) * | 2004-05-12 | 2007-04-17 | Abbott Laboratories | Tri- and bi-cyclic heteroaryl histamine-3 receptor ligands |
JP2008513508A (en) | 2004-09-21 | 2008-05-01 | シンタ ファーマシューティカルズ コーポレーション | Compounds used for inflammation and immunity related applications |
US20100016353A1 (en) | 2004-10-07 | 2010-01-21 | Kirk Russell Henne | Benzoimidazole derivatives useful as antiproliferative agents |
AU2007234382B2 (en) | 2006-04-05 | 2011-06-09 | Novartis Ag | Combinations comprising BCR-ABL/C-KIT/PDGF-R TK inhibitors for treating cancer |
CN101679422A (en) * | 2007-03-28 | 2010-03-24 | 阵列生物制药公司 | Imidazo[1,2-a]pyridine compounds as receptor tyrosine kinase inhibitors |
WO2010039825A2 (en) * | 2008-10-01 | 2010-04-08 | Array Biopharma Inc. | IMIDAZO[1,2-a]PYRIDINE COMPOUNDS AS RECEPTOR TYROSINE KINASE INHIBITORS |
-
2008
- 2008-03-27 BR BRPI0809998A patent/BRPI0809998B8/en not_active IP Right Cessation
- 2008-03-27 PL PL08744440T patent/PL2137184T3/en unknown
- 2008-03-27 EP EP08744440.2A patent/EP2137184B1/en active Active
- 2008-03-27 PT PT87444402T patent/PT2137184E/en unknown
- 2008-03-27 CA CA2682981A patent/CA2682981C/en not_active Expired - Fee Related
- 2008-03-27 CN CN201310054054.1A patent/CN103214482B/en not_active Expired - Fee Related
- 2008-03-27 UA UAA200910891A patent/UA101611C2/en unknown
- 2008-03-27 US US12/593,879 patent/US8138181B2/en not_active Expired - Fee Related
- 2008-03-27 RU RU2009140407/04A patent/RU2467008C2/en not_active IP Right Cessation
- 2008-03-27 WO PCT/US2008/058395 patent/WO2008124323A1/en active Application Filing
- 2008-03-27 RS RS20130316A patent/RS52862B/en unknown
- 2008-03-27 MY MYPI20094106A patent/MY157724A/en unknown
- 2008-03-27 CN CN200880018702A patent/CN101679423A/en active Pending
- 2008-03-27 AU AU2008237507A patent/AU2008237507B2/en not_active Ceased
- 2008-03-27 ES ES08744440T patent/ES2420113T3/en active Active
- 2008-03-27 NZ NZ580327A patent/NZ580327A/en not_active IP Right Cessation
- 2008-03-27 JP JP2010502204A patent/JP5374492B2/en not_active Expired - Fee Related
- 2008-03-27 DK DK08744440.2T patent/DK2137184T3/en active
- 2008-03-27 MX MX2009010728A patent/MX2009010728A/en active IP Right Grant
- 2008-03-27 KR KR1020097022907A patent/KR101538179B1/en active IP Right Grant
- 2008-03-28 TW TW097111550A patent/TWI429434B/en not_active IP Right Cessation
-
2009
- 2009-10-01 IL IL201300A patent/IL201300A0/en active IP Right Grant
- 2009-10-27 CO CO09120874A patent/CO6251377A2/en active IP Right Grant
- 2009-11-02 ZA ZA2009/07674A patent/ZA200907674B/en unknown
-
2010
- 2010-06-29 HK HK10106345.7A patent/HK1140200A1/en not_active IP Right Cessation
-
2013
- 2013-06-28 CY CY20131100527T patent/CY1114277T1/en unknown
- 2013-07-10 HR HRP20130660AT patent/HRP20130660T1/en unknown
Patent Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP1235825B1 (en) * | 1999-11-30 | 2006-01-25 | Pfizer Products Inc. | Novel benzoimidazole derivatives useful as antiproliferative agents |
US20050239822A1 (en) * | 2002-10-08 | 2005-10-27 | Gruenenthal Gmbh | Substituted C-imiadazol[1,2-a] pyridin-3-yl-methylamines |
US20050256309A1 (en) * | 2004-05-12 | 2005-11-17 | Altenbach Robert J | Tri-and bi-cyclic heteroaryl histamine-3 receptor ligands |
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
RU2467008C2 (en) | IMIDAZO[1, 2-a]PYRIDINE COMPOUNDS AS INHIBITORS OF RECEPTOR TYROSINKINASES | |
JP2010523576A5 (en) | ||
CN108349940B (en) | Bruton's tyrosine kinase inhibitors | |
CA2965517C (en) | Indole carboxamides compounds useful as kinase inhibitors | |
DK2651939T3 (en) | Substituted N- (1H-indazol-4-yl) imidazo [1,2-a] pyridine-3-carboxamide as Type-III-RECEPTOR-tyrosine kinase inhibitors | |
DK2686310T5 (en) | Benzodioxan-INHIBITORERAFLEUKOTRIEN PRODUCTION | |
CA2860765C (en) | Pyrazinecarboxamide compound | |
KR20170123631A (en) | Benzazepine dicarboxamide compound | |
JP2012500277A5 (en) | ||
KR20150118148A (en) | Trk-INHIBITING COMPOUND | |
KR102388312B1 (en) | Aminopyrimidine compound, preparation method and use thereof | |
WO2014014874A1 (en) | Pyrazole derivatives which inhibit leukotriene production | |
JP2012525395A5 (en) | ||
JP2015500275A5 (en) | ||
JP2009529047A5 (en) | ||
JP2009533440A (en) | CGRP antagonist salt | |
KR20180032611A (en) | TGF beta receptor antagonist | |
JP2023518830A (en) | Indazole compounds and related uses | |
WO2020203610A1 (en) | Use of t-type calcium channel blocker for treating rheumatoid arthritis | |
JP7197206B2 (en) | Triazolotriazine derivatives used as A2A receptor antagonists | |
JP2023538608A (en) | 1H-pyrrolo[3,2-C]pyridine and 1H-pyrrolo[2,3-C]pyridine derivatives as TLR9 inhibitor inhibitors for the treatment of fibrosis | |
JP2023517539A (en) | Compounds targeting RNA binding proteins or RNA modifying proteins | |
WO2020203609A1 (en) | Use of t-type calcium channel blocker for treating pruritus | |
JP7426486B2 (en) | Heterocyclic compounds as modulators of stimulator of interferon genes (STING) | |
CN112074511B (en) | Substituted benzodiazoles and their use in therapy |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
MM4A | The patent is invalid due to non-payment of fees |
Effective date: 20210328 |